Comparative efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF) and concentrated growth factors (CGF) for female pattern hair loss (FPHL): a prospective multicenter randomized clinical trial.
J Dermatolog TreatApr 27, 2026 (epub)
Clinical ResearchDermatology
Man Li, Yue Bai, Zhenzhen Ye et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter randomized controlled trial evaluated the efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF), and concentrated growth factors (CGF) in treating female pattern hair loss (FPHL). Among 74 patients, CGF and i-PRF showed significantly greater increases in target area hair count (TAHC) at 24 weeks compared to PRP, with CGF at 27.11% and i-PRF at 26.54% versus PRP at 14.53%.
Key findings
- CGF and i-PRF resulted in significantly greater TAHC increases compared to PRP (27.11% and 26.54% vs 14.53%; p < 0.05).
- All treatment groups showed significant within-group increases in TAHC from baseline (all p < 0.05).
- The i-PRF group had the lowest adverse event rate among the treatments.
- VEGF concentration positively correlated with TAHC increase (r = 0.527, p < 0.05).
Why it matters
The findings suggest that CGF and i-PRF may be more effective options for managing FPHL compared to PRP, potentially guiding treatment decisions in dermatology. Understanding the role of growth factors like VEGF could enhance therapeutic strategies.